Tirzepatide in obesitythe surmount clinical study program The GLP-1RA liraglutide has been approved for the pharmacological treatment of obesity and various other GLP-1RA may be approved in the future for this indication as well (3941, 81)
Eur J Clin Invest 2018
Mounjaro suits adults who meet the NICE eligibility criteria (BMI of at least 35, or 32.5 for some ethnicities, with weight-related health problems), and adults using private services who have a BMI of at least 30, or 27.5 with health complications
CrossRef Integrated lifestyle management to mitigate MASLD risk in patients with chronic kidney disease: a prospective cohort study Chao Yan, Xinxin Shen, Shaojie Han, Jinzheng He, Tongxu Wang, Xiaobing Gong, Jindong Ding Petersen Journal of Translational Medicine .2026;[Epub] CrossRef Retatrutide in type 2 diabetes mellitus and obesity: an overview Theodoros Panou, Evanthia Gouveri, Djordje S
They're formulated specifically for patients who want metabolic benefits (improved blood sugar control, inflammation benefits, cardiovascular support, etc.) while maintaining their current weight
